Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced that interim data from the Phase 1B clinical trial of its CRS-207 cancer immunotherapy in combination with chemotherapy as a front line treatment for malignant pleural mesothelioma will be presented at the International Mesothelioma Interest Group (iMig) Conference to be held in Cape Town, South Africa, October 21-24, 2014.
Help employers find you! Check out all the jobs and post your resume.
